Clinical trialsCompany release

Azitra's ATR-04 Clears Cohort 1 Safety Review, Widening Eligibility to MEK Inhibitor Rash

🇺🇸 Azitra, Inc. (AZTR) · Thu 12 Nov 2026

A safety review committee has recommended moving Azitra's ATR-04 Phase 1/2 trial to Cohort 2, as the company reports a $3.0 million third-quarter net loss.

Azitra, Inc. reported its third-quarter 2026 results on 12 November. The company said its safety review committee had recommended that the Phase 1/2 trial of ATR-04 advance to Cohort 2. ATR-04 is a live biotherapeutic aimed at skin rash associated with cancer therapy.

Eligibility for the trial now includes rash linked to KRAS and MEK inhibitors, among them cases in patients with neurofibromatosis type 1. This widens the population the study can enrol beyond its original scope.

Azitra expects topline data from Cohort 1 in the fourth quarter of 2026. It also expects results for ATR-COSF, its cosmetic ingredient programme, by the end of the year.

The company reported a net loss of $3.0 million for the quarter and cash of $3.8 million at quarter-end. The source summary gives no further detail on the cash runway, trial size or dosing.

What it means for your team

  • Cohort 1 topline data, expected in Q4 2026, will be the first public clinical readout for ATR-04 and a key checkpoint for its safety profile.
  • Live biotherapeutics are regulated as biological medicinal products, so safety committee recommendations and cohort escalation decisions are closely watched by pharmacovigilance and clinical safety teams.
  • Extending eligibility to KRAS and MEK inhibitor-associated rash broadens the potential use of ATR-04 alongside targeted oncology therapies, a point for market-access teams tracking supportive-care products.
  • The company's reported cash of $3.8 million is a factor to weigh when assessing the programme's timeline.

Company's press release (SEC filing): Azitra, Inc. ↗

Article written by VigiEye from the official source (Azitra, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →